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Human Immunodeﬁciency Virus-1 (HIV-1) encodes a 27 kDa Negative Factor or Nef protein, which is
increasingly proving to be a misnomer. Nef seems to be crucial for AIDS progression as individuals
infected with nef-deleted strain of HIV were reported to become Long Term Non Progressors (LTNP).
These ﬁndings necessitate tracing of Nef's footprint on landscape of cellular transcriptome favoring HIV-1
pathogenesis. We have tried to explore effect of Nef on cellular gene expression proﬁle in conjunction
with rest of HIV-1 proteins. Our results show that 237 genes are differentially regulated due to the
presence of Nef during infection, which belong to several broad categories like “signaling”, “apoptosis”,
“transcription” and “lipid metabolism” in gene ontology analysis. Furthermore, our results show that Nef
causes disruption of lipid content in HIV-1 infected T cells. Molecular inhibitors of lipid metabolism like
Atorvastatin and Ranolazine were found to have profound effect on wild type virus as compared to nef-
deleted HIV-1. Thus our results suggest that interference in lipid metabolism is a potential mechanism
through which Nef contributes in enhancing HIV-1 pathogenesis.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
According to the latest global UNAIDS report, there are nearly 35
million people infected with HIV living today, even after three de-
cades of intense research on this virus. This necessitates further
studies to unravel the unsolved mysteries in existing literature
about deleterious effects of the virus. HIV-1, in addition to regular
structural and regulatory proteins expresses several accessory
proteins namely Nef, Vpr, Vpu and Vif. HIV-1 Nef has been credited
as one of the most important proteins for viral life cycle and
pathogenesis. It is a ~27 kDa, multifunctional adaptor protein
lacking enzymatic activity [1,2]. Nef is produced early and abun-
dantly in the viral life cycle right after proviral transcriptional
activation [1,3]. Nef participates in an array of functions including
down-regulation of CD4, and class I and II Major Histocompatibility
Complex, stimulation of viral replication and enhancement of
virion infectivity [1e3]. Presence of non-functional, truncated or
mutant Nef during infection by HIV-1 has been shown to decrease
viral infectivity and pathogenicity [4]. Nef-deleted HIV was also
found to exist in humans having barely detectable viral load [4,5].ahoo.co.in (D. Mitra).
r Inc. This is an open access articleLong Term Non Progressors (LTNP)/Slow progressors (SP) of HIV
infectionwere detected to be carrying mutations in nef region [6,7].
So it is evident that lack of Nef or its partial functionality contrib-
utes to non-progressive HIV infection, projecting Nef as a subject of
intense studies.
Numerous studies have therefore, been directed towards Nef's
effects on transcription of viral and cellular genes. While few re-
ports point towards direct effect of Nef on enhancing transcription
from HIV-1 promoter [8,9], there are also reports revealing Nef
induced modulation of cellular transcriptome. Exogenous expres-
sion of Nef followed by gene expression studies have been done on
a variety of cells like Jurkat [10], HeLa [11], astrocytes [12] and U937
[13]. All such studies seem to have neglected the complex molec-
ular interaction between Nef and other viral proteins [14] having
simultaneous effect on HIV infected host cells. Thus it is important
to study Nef's effect on host cell in presence of rest of the viral
proteins. In the present study, we have compared the gene
expression proﬁle betweenwild type and nef-deleted virus infected
T-cells in order to identify genes modulated due to presence Nef
during HIV-1 infection. Interestingly, our results indicate changes
in a number of genes including that of lipid metabolism related
genes due to HIV-1 infection in presence of Nef. Consequently we
also found lowering of lipid content of T cells due to HIV-1 infection
suggesting a role of nef in regulating lipid metabolism. Moreover,under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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lipid metabolism at different stages, inhibitedWTHIV-1 replication
more than nef-deleted HIV-1. Thus, our results implicate Nef in
perturbation of lipid content of CD4þ T cells during HIV-1 infection.
2. Materials and methods
2.1. Plasmids, cell lines and transfections
pNL4-3, a molecular clone of HIV-1 was received from NIH AIDS
reagent program, USA [17]. Nef-deleted molecular clone of HIV-1,
pNL4-3Dnef was a kind gift from Dr J C Guatelli [18]. NL4-3 Nef
cloned in pCDNA (pCDNA-Nef) was a kind gift from Dr. M. Federico
[19]. Cell lines HEK-293T and U937 were obtained from NCCS cell
repository, India. Human CD4þ T reporter cell line CEM-GFP [20]
and HeLa based CD4þ reporter cell-line TZM-bl was received from
NIH AIDS reagent program, USA [21]. Cells were transfected with
pCDNA-Nef in increasing concentrations using XtremeGene HP
(Roche Applied Sciences, Germany) according to the manufac-
turer's protocol. Cells were harvested 60 h post-transfection for
quantitation of GFP expression.
2.2. HIV-1 infection and quantitation
CEM-GFP, U937 and TZM-bl were given 0.5 multiplicity of
infection (MOI) of Dnef or WT HIV-1 NL4-3 as described previously
[22]. HIV-1 replication was quantitated using p24gagantigen cap-
ture ELISA (Advanced Biosciences Laboratories, USA) according to
manufacturer's instructions. HIV-1 LTR promoter activity after
infection was monitored in TZM-bl by luciferase assay as described
earlier [23]. In CEM-GFP cells, GFP expression as a measure of gene
expression from LTR promoter due to HIV-1 infection was moni-
tored by quantitating GFP expression using M5 Microplate multi-
mode reader from Molecular Devices, USA. Zidovudine (AZT),
Atorvastatin and Ranolazine (SigmaeAldrich, USA) were used at
already reported concentration of 5 mM, 10 mM and 50 mM respec-
tively [24e26] during HIV-1 infection.
2.3. Gene expression proﬁling
Total RNA was isolated from uninfected, 0.5 MOI of Dnef or WT
HIV-1 infected CEM-GFP at 72 h in triplicates, using RNeasyMini kit
(Qiagen, Germany). RNA integrity was evaluated using a Lab-on-
Chip-System Bioanalyzer 2100 (Agilent, USA) and was quantiﬁed
using NanoDrop ND-1000 (Thermo, USA). For gene expression
proﬁling, oligonucleotide microarray analysis was performed using
4X44 K Agilent Human Genome microarray (Agilent Technologies,
USA) according to the manufacturer's protocol along with Feature
extraction software, version 9.5.3 e Agilent Technologies, USA. The
data analysis was done using GeneSpring 13 software (Agilent,
USA). This microarray data has been deposited to the GEO re-
pository and is available via the accession number GSE76793 at
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc¼GSE76793.
RNA extraction and qRT-PCR for selected genes was done as re-
ported [23].
2.4. Lipid quantitation using ﬂow cytometry and
spectrophotometry
Uninfected CEM-GFP cells along with 0.5 MOI Dnef or WT HIV-1
infected cells were harvested 72 h post infection, ﬁxed with 1%
Paraformaldehyde and stained with 0.3% Oil Red O (ORO) (Sigma,
USA) in 60% Isopropanol as described earlier [27]. Acquisition and
analysis of GFP expression and ORO staining along with controls
were quantiﬁed on FACS Canto II ﬂow cytometer using FACS Divasoftware (Becton Dickinson, USA). Histograms were plotted using
FlowJo Software (Tree Star Inc., USA). To quantitate ORO stain using
spectrophotometer, stained or unstained control cells were lysed
using lysis buffer (50mMTriseHCl pH 7.4, 5 mMEDTA, 0.12MNaCl,
0.5% NP40, 0.5 mMNaF,1 mMDTT, 0.5 mM PMSF) on ice for 45min.
100 ml of lysate was read for optical density at 518 nm in M5
microplate multimode reader.
2.5. Antibodies and immunoblotting
Cells were lysed in lysis buffer as mentioned above. Equal
amounts of protein were taken from cell lysates and were resolved
by SDS-PAGE followed by immunoblotting for Nef and GAPDH. A
polyclonal anti-Nef serumwas obtained from Dr S. Jameel [28] as a
kind gift whereas antibody speciﬁc for GAPDH was obtained from
Santa Cruz Biotechnology, USA.
2.6. Statistical analysis
Each individual experiment was repeated at least three times.
The error bars in the ﬁgures represent the mean ± S.D. of three
independent experiments. Statistical analysis of the experimental
data was performed using Student's t test with the levels of sig-
niﬁcance denoted by p-value.
3. Results
3.1. Nef induces HIV-1 replication and transcription in infected cells
Although Nef has been reported in enhancement of virus
replication and infectivity [1,2], we wanted to reconﬁrm its role in
HIV-1 replication and gene expression in different microenviron-
ments exempliﬁed by different cell lines infected with HIV-1. Su-
pernatant from nef-deleted or wild-type HIV-1 NL4-3 virus infected
cells were collected and virus production was assessed by
measuring p24 antigen. In both the cell lines nef-deleted virus
production seems to lag behind WT HIV-1 production (Fig. 1A, B).
Being a positive strand RNA virus, transcription from HIV-1 LTR
promoter has a direct bearing on its replication. Thus, we also
measured transcriptional activity from HIV-1 LTR promoter in re-
porter cell lines CEM-GFP and TZM-bl. Analysis of GFP expression
and luciferase activity in these infected cell lines exhibit enhanced
transcriptional activity due to presence of Nef in WT HIV-1 infec-
tion as compared to nef-deleted virus infection (Fig. 1C and D). The
difference between Dnef HIV-1 and WT HIV-1 is reﬂected maxi-
mally at 72 h post infection in CEM-GFP (Fig. 1A and C). So this time
point was chosen to explore how Nef can affect cellular gene
expression proﬁle during HIV-1 infection progression.
3.2. Gene expression proﬁling of nef-deleted and wild type HIV-1
infected CEM-GFP cells
Microarray technology used as described above enabled us to
visualize gene expression proﬁle of nef-deleted and wild type virus
infected cells thereby identifying genes speciﬁcally affected due to
presence of Nef amongst all other viral proteins. On comparison of
WT HIV-1 infected CEM-GFP (WTHI) with uninfected cells (UI); we
obtained a gene list (DEG-1) of 231 signiﬁcantly deregulated genes
[Supplementary Data Table 1]. We also obtained another gene list
(DEG-2) of 30 signiﬁcantly deregulated genes due to nef-deleted
HIV-1 infection of CEM-GFP cells (DNHI) as compared to uninfected
cells (UI) [Supplementary Data Table 2]. Then we used Dnef HIV-1
infected cell gene expression proﬁle as control and compared it
with WT HIV-1 infected cell gene expression proﬁle. We obtained a
3rd gene list (DEG-3) of 237 signiﬁcantly deregulated genes
Fig. 1. nef-deleted HIV-1 lags behind WT HIV-1 in terms of peak and kinetics of infection progression. HIV-1 replication was quantitated using supernatants of 0.5 MOI Dnef
HIV-1 (DNHI) or WT HIV-1 infected cells (WTHI) at different hours post infection by p24 antigen capture ELISA in (A) CEM-GFP cells (B) U937 cells. Quantitation of transcriptional
activity from HIV-1 LTR promoter due to DnefHIV-1 or WT HIV-1 infection by measuring (C) GFP expression in CEM-GFP cells, (D) luciferase activityin TZM-bl cells. **p  0.05
***p  0.01.
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analyzed for number of common and unique genes in each of them
by plotting a Venn diagram (Fig. 2A).We found 98 genes exclusively
deregulated due to presence of Nef during HIV-1 infection pro-
gression. There are also 123 genes which are common to WTHI vs
DNHI and WTHI vs UI indicating that these genes are deregulated
due to HIV-1 infection and probably also due to presence of Nef. To
study the precise effect of Nef on gene expression proﬁle of HIV-1
infected cells we further analyzed the third gene list i.e., DEG-3.
Normalized intensity of expression of these genes in all the sam-
ples is depicted in a heat map (Fig. 2B). Wemanually then re-sorted
the differentially expressed genes in categories like “Apoptosis”,
“Transcription”, “Signaling” (Supplementary Fig. 1) and “Lipid
metabolism” according to their associated GO term. Mean
normalized intensities of lipid metabolism genes are represented in
heat map (Fig. 2C) as we wanted to study them further. All these
genes belonging to these four broad categories are also represented
through cytoscape (Supplementary Fig. 2) which allows depiction
of direction of expression change and corresponding interaction
readily.
3.3. Validation of microarray results for selected lipid metabolism
related genes
Amongst the 33 genes of DEGs belonging to category “lipid
metabolism”, we selected randomly 10 genes for validation
showing a wide range of modulation pattern in microarray data.
Validation of results obtained by microarray analysis was per-
formed by qRT-PCR of selected deregulated genes. The transcript
levels of all 10 genes weremeasured by qRT-PCR using GAPDH as an
internal control. We found strong correlation between the dereg-
ulation trend observed in microarray and the qRT-PCR data (Fig. 3).
Also to be noted here is that, a number of genes like formin binding
protein 1 (FNBP1), sterol O-acyltransferase 2 (SOAT2), carnitine O-
octanoyl transferase (CROT), fatty acid binding protein 3 (FABP3),
peroxisome proliferator-activated receptor alpha (PPARa), 1-
acylglycerol-3-phosphate O-acyltransferase 3 (AGPAT3), delta(4)-
desaturase sphingolipid 1 (DEGS1) etc, are directly involved in
lipid binding and oxidation.3.4. Nef alters lipid constitution of HIV-1 infected cells
After conﬁrming deregulation of several lipid metabolism
related genes in microarray data, we have then looked at the fate of
this deregulation on cellular physiology. Signiﬁcant decline in Oil
Red O (ORO) staining of Wild type infected CEM-GFP cells as
compared to nef-deleted HIV-1 infected or uninfected cells was
observed in ﬂow cytometry based analysis (Fig. 4A). However, there
was signiﬁcant GFP expression in CEM-GFP due to nef-deleted HIV-
1 or Wild-type HIV-1 infection (Fig. 4B) as compared to uninfected
cells. Same data was plotted using Mean Fluorescent Intensities
(M.F.I.) of ORO staining and GFP expression. MFI of ORO staining
indicate that lipid content ofWT HIV-1 infected cells is signiﬁcantly
lower than uninfected or Dnef HIV-1 infected cells (Fig. 4C)
although MFI of GFP expression indicated high levels of infection in
both Dnef HIV-1 and WT HIV-1 infected cells (Fig. 4D).
To further verify the interplay of Nef, we did the quantitation of
ORO staining using spectrophotometry. Expression of increasing
dose of Nef in trans with Dnef HIV-1 revealed gradual decline in
ORO staining as compared to Dnef HIV-1 infected (Fig. 4E). Western
blot for Nef in the lower panel conﬁrmed dose-dependent increase
in Nef expression where GAPDH was used as control. This experi-
ment further proved that Nef induces decline in lipid content
during HIV-1 infection progression. As visualized by GFP expres-
sion, infection levels also increased due to increase in Nef expres-
sion during nef-deleted HIV-1 Infection (Fig. 4F). We then used well
characterized pharmacological inhibitors of lipid metabolism
namely Atorvastatin [15] and Ranolazine [29]. We examined their
ability to affect HIV-1 infection in presence or absence of Nef.
Addition of Atorvastatin (10 mM) and Ranolazine (50 mM) respec-
tively led to signiﬁcant decline in wild type HIV-1 viral particle
production as quantiﬁed by p24 antigen capture ELISA (Fig. 4G
upper panel) as well as in GFP expression (Fig. 4G lower panel).
However, inhibition of virus production or suppression of GFP
expression was not visible to the same extent in Dnef HIV-1
infection (Fig. 4H). The concentrations used for the study did not
induce any visible cytotoxicity in CEM-GFP. Zidovudine (AZT, 5 mM)
was used as a positive control inhibitor.
Fig. 2. Representation of differentially expressed genes in wild type and nef-deleted HIV-1 infected CEM-GFP as identiﬁed from microarray analysis. (A) Venn diagram showing
number of genes common or unique to three different gene lists DEG.1, 2, 3 generated by gene expression proﬁling of uninfected, DNHI or WTHI. (B) Heat map representation of
genes differentially expressed due to presence of Nef during infection. Red and green color show up-regulation and down-regulation respectively from baseline (black color). (C)
Heat map illustration of mean normalized intensity of genes related to Lipid metabolism. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to
the web version of this article).
Fig. 3. Validation of microarray data for selected lipid metabolism related genes using
qRT-PCR. qRT-PCR analysis of selected lipid metabolism genes from DEG3 was per-
formed using RNA extracted from uninfected, DNHI, and WTHI CEM-GFP cells. The fold
change values in the bar graphs depict the changes in gene expression in infected cells
over the expression levels in uninfected cells normalized to GAPDH. The data is
representative of three biological replicates. **p  0.05, ***p  0.01.
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Antiretroviral therapy currently available to AIDS patients
include inhibitors that block fusion of viral and host membrane,
inhibitors of viral reverse transcriptase, protease and integrase
activity, thereby impeding important steps in viral life cycle.
Meanwhile the focus on identifying an alternative target for anti-
HIV drug discovery has been inclined towards Nef due to
increasing literature about its importance in viral life cycle [30].
Various other reports [2] and our preliminary results conﬁrms Nef's
integral role in viral replication and transcription irrespective of
different microenvironments posed by different cell lines like CEM-
GFP, U937 or TZM-bl.
There have been several reports on Nef's interaction with other
viral proteins. These interactions can alter activities of Nef and rest
of the viral proteins [14]. For instance protease mediated cleavage
of Nef can alter its protein binding ability [31]. NefeTat interaction
can cause enhanced gene expression from HIV-1 LTR promoter
[8,9]. Either way, the interactions between Nef and other viral
proteins can have an effect on host cellular machinery. Thus to
explore the sole effect of Nef on viral and cellular transcription in
Fig. 4. Nef is responsible for decrease in cellular lipid content observed during HIV-1 infection, and its effect can be abrogated by pharmacological inhibitors of lipid metabolism. (A)
Histogram of FACS based quantitation of Oil Red O staining of uninfected, DNef HIV-1 (DNHI) or WT HIV-1 infected (WTHI) CEM-GFP cells showing decline in ORO staining of WT
HIV-1 infected cells as compared to DNef HIV-1 infected or uninfected cells. (B) Histogram of FACS based quantitation of GFP expression of uninfected, DNef HIV-1 or WT HIV-1
infected CEM-GFP showing enhanced WT HIV-1 infection and DNef HIV-1 infection. The results of one representative experiment out of three are shown (C) MFI of ORO staining
indicates statistically signiﬁcant decline in lipid content of WT HIV-1 infected CEM-GFP cells. (D) MFI of GFP expression indicates infection progression in DNef HIV-1 or WT HIV-1
infected CEM-GFP cells. (E) Increasing dose of Nef in trans with DNHI indicated gradual decrease in lipid content of CEM-GFP cells. (F) Gradual enhancement of GFP seen in nef-
deleted HIV-1 infected cells due to expression of increasing dose of Nef in Trans. (G) WTHI CEM-GFP and (H) DNHI CEM-GFP treated with Atorvastatin (10 mM) and Ranolazine
(50 mM). Zidovudine (AZT) (5 mM) was taken as positive control. 72 h post-infection, supernatant was checked for viral particle production inhibition (upper panel) and cell lysate
was analyzed for GFP expression (lower panel).***p  0.01, **p  0.05.
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imperfect biological microenvironment and physiologically extra-
neous. Hencewe compared expression proﬁles of nef-deleted HIV-1
and WT HIV-1 infected cells which yielded information on a set of
genes which are signiﬁcantly deregulated due to presence of Nef
during infection progression. Our model also corroborates with the
methodology adopted to study the effect of Nef on infectivity
during HIV-1 infection very recently [32,33]. Surprisingly on com-
parison of DNHI with uninfected cells we found only 31 genes
deregulated, indicating the lower potency of nef-deleted HIV-1. It
also reinstates our results that Nef can exercise transcriptional
control and thus affect HIV-1 replication. While an array of reports
point to Nef's role in signaling and apoptosis as described in pre-
vious reviews [1,34,35], there are only a few studies which points toNef's interference in cellular transcription or lipid metabolism
disruption. We found genes belonging to lipid metabolism as a
subset of genes differentially expressed due to presence of Nef
during HIV-1 infection. We validated our microarray results by
checking themRNA expression levels of a few of them through qRT-
PCR. This implicates Nef in directing disruption of cellular lipid
content. Oil Red O staining of nef-deleted and WT HIV-1 infected
cells conﬁrmed our hypothesis that Nef indeed disrupts lipid
constitution of HIV-1 infected cells. Our observation falls in accor-
dance with a prior study where over expression of Nef in HeLa lead
to disruption of cellular lipid constitution [11]. However additional
experiments are necessary to identify precise chemical nature of
lipids and impact of their deregulation on HIV-1 infection pro-
gression. Another concurrent study done on plasma lipid levels of
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in abundance of High Density Lipoproteins (HDL), phosphati-
dylserine and sphingolipids [36].While our study differs from these
in terms of not only reporting the deregulation of lipid metabolism
genes at transcription level but also showing down regulation of
cellular lipid content. Atorvastatin is classically known to inhibit
cholesterol synthesis and can therefore interfere in lipid meta-
bolism in more than one ways and is also reported to inhibit HIV-1
[37]. Ranolazine on the other hand inhibits fatty acid oxidation and
is widely used as a drug against angina [29]. As wild type HIV-1 can
utilize lipid metabolism for its own replication, inhibitors of lipid
metabolism can potentially suppress HIV-1 replication. Our results
highlight the association of lipid metabolism disruption with
presence of Nef which is why Dnef HIV-1 replication is inefﬁciently
inhibited in presence of Atorvastatin and Ranolazine.
In view of the number of pathways in which Nef aids HIV
infection progression, lipid metabolism perturbation can poten-
tially contribute to some of the common clinical features seen in
AIDS patients including weight loss, wasting, and immunodeﬁ-
ciency. This study implicates Nef in lipid metabolism perturbation
to enhance HIV-1 replication. Our study thus reinstates Nef as a
pivotal therapeutic target to enhance the quality of life of AIDS
patients.
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